Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 43

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
,406 Other income (expense), net138 1,519 — 1,657 Income tax expense— — 4,220 4,220 Net income (loss)31,321 144 (14,610)16,855 Nine Months Ended September 30, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$30,519 $1,711 $— $32,230 Other revenue392 3 — 395 Provision for credit losses10,777 — — 10,777 Loss on impairment of intangible assets— 5,771 — 5,771 Interest expense820 7 2,687 3,514 Pharmaceutical manufacturing, research and development expense— 1,635 — 1,635 Depreciation and amortization expense— 1,106 63 1,169 Change in fair value of acquisition-related contingent consideration— (4,900)— (4,900)General and administrative expense254 2,179 6,164 8,597 Other income (expense), net4,135 — (411)3,724 Income tax expense— — 2,170 2,170 Net income (loss)23,195 (4,084)(11,495)7,616 Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and corporate employees, which have been included for purposes of reconciling to the consolidated amounts. The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):September 30, 2025December 31, 2024Total AssetsFinance receivables$266,580 $299,248 Pharmaceutical development and other— 7,786 Holdings Company and other22,782 25,201 Total$289,362 $332,235 

27

ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements, and the MD&A included in our Annual Report on Form 10-K for